HomeAI · summaries
Storia in 2 fonti
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed a phase 3 flop in the KRAS G12C inhibitor’s smaller-op | As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed what could be a major stumble in the KRAS G12C inhibitor’s smaller-opportunity indication of colorectal cancer.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk.
- ·
fiercepharma.com
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed a phase 3 flop in the KRAS G12C…